February 23, 2017

OTTAWA, ONTARIO–(Marketwired – Feb 23, 2017) – PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and […]

by

Medical Marijuana Inc (OTCMKTS:MJNA) is a central brand in the cannabis patch. The stock has performed very well in this important year for the space. We’ve seen renewed strength in recent weeks with an extra pop late this past week as the company announced that its subsidiary company HempMeds has formed a new business in […]

by

CV Sciences Inc (OTCMKTS:CVSI) has been pushing higher along with other stocks in the cannabis-related space in recent days as we near an expansion of the overall footprint of the industry in November. The Company just put out an in-depth shareholder communique that further reinforces the bull case around this name as well. In all, […]

by

ChineseInvestors.com Inc (OTCMKTS:CIIX) is a new flavor in the MJ stock group that just took flight. The stock has doubled in recent days. The catalyst appears to be the company’s announcement that it will launch the world’s first Cannabidiol (CBD) health products online store in the Chinese Language by the end of January 2017 under […]

by

VANCOUVER, British Columbia, Feb. 22, 2017 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) is pleased to announce encouraging results from a Phase 2a study evaluating the safety and efficacy of cannabidiol (“CBD”), a primary constituent of the marijuana plant, for the treatment of acute (Grade 3-4) Graft versus Host Disease (“GvHD”). In the present […]

by